Skip to content

12 results for "Meta-analysis: What did research on Cannabis find in January 2026?"

The Paradoxical Effect of Cannabis Use on Cognition in Chronic Psychotic Disorders

Pathophysiology January 27, 2026 Fiorela Gorea, Martina Pelle, Federico Fiori Nastro et al.

Background/Objectives: Cannabis use has a particularly high prevalence in individuals with psychotic disorders. Although cannabis use is generally associated with cognitive impairments in the general population, its impact on cognition in psychosis remains controversial. This study aimed to investigate the association between cannabis use and cognitive performance in a cohort of individuals...

Δ 9 -Tetrahydrocannabinol-induced enhancement of reward responsivity via mesocorticolimbic modulation in squirrel monkeys.

bioRxiv : the preprint server for biology January 24, 2026 Kwang-Hyun Hur, Lisa D Nickerson, Jack Bergman et al.

Δ 9 -tetrahydrocannabinol (THC)-containing products are widely used recreationally, partly due to THC's ability to enhance the appetitive (i.e., rewarding) properties of diverse stimuli. However, the neural mechanisms through which THC modulates reward-related processing remain poorly understood. Here, we used a Pavlovian paradigm in adult squirrel monkeys (3males, 1female) to associate a...

Cannabis-based medicines for chronic neuropathic pain in adults.

The Cochrane database of systematic reviews January 19, 2026 Gülay Ateş, Patrick Welsch, Petra Klose et al. 5 citations

Estimates of the population prevalence of chronic pain with neuropathic components range from 6% to 10%. Current pharmacological treatments for neuropathic pain help only a minority. New treatments are needed. Cannabis is increasingly promoted in the media as a treatment for chronic pain. This is an update of a review first published in 2018. To assess the benefits and harms of cannabis-based...

THC induced similar physiological effects on HIV transgenic rats and their controls without affecting HIV-induced deficits in effortful motivation.

Journal of Cannabis Research January 2, 2026 Sunitha Vemuri, Samantha M. Ayoub, Arpi Minassian et al.

Cannabinoids have proven to useful for attenuating adverse effects of HIV. People living with HIV use cannabis at higher rates, with evidence suggesting it alleviates physiological symptoms such as nausea, loss of appetite, etc.. Cannabis can alter physiology as well as essential behavioral functions such as motivation. This study investigated the effect of delta-9-tetrahydrocannabinol (THC),...

Detection of Δ9-Tetrahydrocannabinol Impairment Using Resting-State Functional Near-Infrared Spectroscopy: A Randomized Clinical Trial.

JAMA Network Open January 2, 2026 Moshe Berchansky, A Eden Evins, Bryn Evohr et al. 1 citation

The primary psychoactive compound in cannabis, ∆9-tetrahydrocannabinol (THC) induces intoxication and functional impairment, raising safety concerns in driving. The traditional impairment detection method, behavioral field sobriety tests (FSTs), are subject to bias. To determine whether resting-state functional near-infrared spectroscopy (fNIRS) can detect THC-related impairment with greater...

Cognitive performance recovery following marijuana cessation in NCAA division I athletes.

Frontiers in sports and active living 2026 Brandon A Ally, Paul A Mentele, Scott A Wylie

Cannabis use is increasingly common among collegiate athletes. While acute tetrahydrocannabinol (THC) effects are well documented, the chronic impact on game-speed cognition, defined as the ability to perceive, decide, and act within sub-second windows, remains poorly quantified. The current study examined whether chronic THC use degrades football specific game-speed cognition and reaction...

Randomized trial of delta-9-tetrahydrocannabinol (THC) versus placebo to augment the effects of prolonged exposure therapy on fear extinction learning in post-traumatic stress disorder: Study rationale and protocol.

Contemporary Clinical Trials 2026 Christine A Rabinak, Paul E Kilgore, Mark A Lumley et al.

Prolonged exposure (PE) therapy is effective for PTSD, yet dropout and partial response remain concerning. Preclinical and human studies suggest Δ9-tetrahydrocannabinol (THC) enhances fear extinction and recall through brain cannabinoid receptor activation in fear processing. Examine whether synthetic THC (dronabinol) augments PE effectiveness. Double-blind, placebo-controlled, trial with...

Regional and cannabis-related differences in prefrontal multiscale entropy of resting-state EEG.

Clinical Neurophysiology Practice 2026 William T Creel, Colleen A Brenner, Richard E Hartman

Entropy analysis of electroencephalographic (EEG) data provides insight into the complexity of neural activity. This study primarily examined whether cannabis use frequency is associated with alterations in multiscale entropy (MSE) in the prefrontal cortex (PFC) and mapped baseline MSE differences across cortical regions. Resting-state EEG was collected from 57 adults: non-users (n = 18),...

What Do Thirty Years of Neuroimaging Research Tell Us About Recreational Cannabis Use and Brain Integrity? A Narrative Review of the Multimodal Neuroimaging Evidence to Date.

Substance Abuse and Rehabilitation 2026 Ethan Murphy, Chao Suo, Govinda Poudel et al.

The consumption of cannabinoids is highly prevalent and has been associated with altered structural, functional, and metabolic brain integrity, measured using PET and neuroimaging tools. However, the current neuroimaging evidence has been summarized by distinct modalities that measure different metrics of brain integrity, precluding a comprehensive understanding of the underlying neurobiology....

Addressing US Demand for Psychedelic Medicines in the Face of Scientific Uncertainty.

The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics 2026 Holly Fernandez Lynch, Xinping Hu, Alison Bateman-House 2 citations

Psychedelic medicines hold the promise of therapeutic benefit for many suffering from serious unmet mental health needs, leading to substantial demand even before these drugs receive FDA approval based on demonstrated safety and effectiveness for particular conditions. Recognizing FDA approval as the ideal path for psychedelics intended for medical use and drawing on lessons from medical...

Partydrogen im Überblick

Psychopharmakotherapie 2026 Antonia Bendau, Felix Betzler, Twyla Michnevich et al. 1 citation

Party drugs encompass a broad spectrum of legal and illegal psychoactive substances used in party settings such as clubs, festivals, raves or private gatherings to modulate mood, perception, social interaction and bodily states. Most commonly, alcohol and cannabis are consumed, followed by amphetamine, MDMA (“ecstasy”), cocaine and ketamine. Synthetic cathinones, GHB/GBL (“liquid ecstasy”),...